RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Glaxo Wellcome SA, a subsidiary of GSK Plc, is a company headquartered in Aranda de Duero, Spain. The firm manufactures and markets medicines.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Good health and a happy life is something all people rightly aspire to. They believe everyone on the planet deserves access to quality health care. Finding affordable solutions to today's health care challenges demands cutting-edge science, highly talented and motivated people and above all the ability to innovate. Innovation and continuous improvement are the heartbeat of their company. Their mission is to make health care more affordable, increasing access to important medicines through the provision of high quality small molecule generics, and new biological and new chemical entities.

GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada.

Transcept Pharmaceuticals, Inc. uses its proprietary delivery system to enhance the penetration of drugs, significantly speeding their onset of action. Transcept is developing rapid-acting versions of several major market pharmaceuticals. Hamilton co-invested in the company's first institutional round of funding alongside Montreaux Equity Partners, Peninsula Equity Partners and Vivo Ventures. Investors in subsequent financing rounds include these firms, and New Leaf Venture Partners, Interwest Partners and New Enterprise Associates.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary oral spray technology delivery system offers the patient the potential for (i) more rapid delivery of drugs to the bloodstream allowing for quicker onset of therapeutic effects compared to conventional oral dosage forms; (ii) increased bioavailability of a drug by avoiding metabolism by the liver; (iii) improved drug safety profile by reducing the required dosage, including possible reduction of side effects; (iv) improved dosage reliability; (v) allowing medication to be taken without water; (vi) avoiding the need to swallow as is the case with many medications; and (vii) improved patient convenience and compliance. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.

Galderma Research & Development SNC discovers, develops, and markets therapeutic, corrective, and aesthetic solutions. The company is headquartered in Biot, France.

Zoetis Belgium SA, a subsidiary of Zoetis, Inc., is a Belgian company located in Louvain-La-Neuve. The firm manufactures animal vaccines and prescription medicines.

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical products and wind power generation. The company was founded on November 20, 1987 and is headquartered in Raichur, India.

Taihe Biotech Pharmaceutical Co., Ltd. (Taihe) is a biotechnology new drug development company that specializes in the development of a niche market with its own technology platform for its existing pharmaceutical products (Specialty Pharma) . Taihe adheres to the spirit of sincerity, credit and responsibility, carries out product development, and strictly abides by the latest international regulations to carry out all research and development work. It is expected that the product inspection materials established will meet the requirements of advanced countries, in order to facilitate future entry into the international market and authorization. The international large-scale factory carried out follow-up development and obtained the drug certificate of the target drug in the shortest time. It is hoped that Gengyitai will be synthesized as a “ TDS New Drug Development Company ” and establish a Taiwan drug development industry value chain and success stories.

Luxena Pharmaceuticals, Inc. is an American private company. The firm develops and manufactures pharmaceutical formulation.

Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ.

Inke SA, part of Permira I.P. Ltd., is a Spanish company located in Barcelona. The firm manufactures active pharmaceutical ingredients. It was founded in 1980.\nThe company says this about itself: Inke is a leading global manufacturer of inhalation active pharmaceutical ingredients (APIs) established in 1980 and based in Castellbisbal (Barcelona, Spain). With more than 25 years of experience in respiratory APIs, the company focuses on the development and manufacturing of high–added-value active substances for the pharmaceutical industry for use in inhalation therapies. The company holds great expertise for the treatment of respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). This qualifies Inke to be a key supplier to major generic and branded companies worldwide, having twelve respiratory APIs for inhalation in its portfolio and distributing its products to more than 40 countries including Europe, the US, Japan, Korea, China and Turkey. Inke has been successfully inspected by every major global authority, including the US-FDA since 2002 (latest inspection in March 2023). It is fully EU-GMP compliant and holds ISO 9001 and ISO 14001 certifications. The company has a strong regulatory track-record with 10 Certificates of Suitability (CEPs), 26 EU-DMF, 21 US-DMF, 8 JP-DMF, 11 KR-DMF and 9 CN-DMF.